FDA WARNING_LETTER - Fancy Meds, LLC dba Fancy Meds - August 01, 2025

On September 9, 2025, the FDA issued a Warning Letter to Sunnyvale-based Fancy Meds, LLC (dba Fancy Meds) following a review of the company’s website conducted in August 2025. The FDA found that the company is marketing compounded versions of semaglutide and tirzepatide with false or misleading claims. Specifically, Fancy Meds suggested their products contain the same active ingredients as FDA-approved drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, and implied their products are created with FDA-approved ingredients in a way that suggests equivalence to approved medications. The FDA emphasized that compounded drug products are not FDA-approved and that these claims incorrectly suggest identity or equivalence to approved brands. Under the Federal Food, Drug, and Cosmetic Act (FDCA), specifically sections 502(a) and 502(bb), these products are considered misbranded. The FDA noted that introducing such misbranded drugs into interstate commerce is a violation of sections 301(a) and 301(c) of the FDCA. Fancy Meds is required to take immediate action to correct these violations, including ceasing the use of the misleading language identified. The company must provide a written response to the FDA within 15 working days detailing the steps taken to address the issues and prevent their recurrence. Failure to comply may result in legal action, including product seizure or injunctions.